Development of Resistance to Type II JAK2 Inhibitors in MPN Depends on AXL Kinase and Is Targetable
MPN 对 II 型 JAK2 抑制剂的耐药性发展取决于 AXL 激酶,并且可作为靶向治疗
期刊:Clinical Cancer Research
影响因子:10
doi:10.1158/1078-0432.CCR-23-0163
Tamara Codilupi #, Jakub Szybinski #, Stefanie Arunasalam #, Sarah Jungius, Andrew C Dunbar, Simona Stivala, Sime Brkic, Camille Albrecht, Lenka Vokalova, Julie L Yang, Katarzyna Buczak, Nilabh Ghosh, Jakob R Passweg, Alicia Rovo, Anne Angelillo-Scherrer, Dmitry Pankov, Stefan Dirnhofer, Ross L Levi